Overview

A Dose-Escalation Study Designed to Evaluate the Tolerability, Safety, Pharmacokinetics (PK), and Efficacy of Chronic Topical Ocular Application of INO-8875 in Adults With Ocular Hypertension or Primary Open-Angle Glaucoma

Status:
Completed

Trial end date:
2012-01-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate how tolerable, safe, and effective it is to give INO-8875 eye drops to adults with glaucoma or ocular hypertension.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Inotek Pharmaceuticals Corporation

Treatments:

Adenosine
Ophthalmic Solutions